These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17110237)

  • 1. Apolipoprotein A1 and B.
    Sniderman AD; Marcovina SM
    Clin Lab Med; 2006 Dec; 26(4):733-50. PubMed ID: 17110237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for optimizing lipid management.
    Ballantyne CM
    Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
    Barter PJ; Ballantyne CM; Carmena R; Castro Cabezas M; Chapman MJ; Couture P; de Graaf J; Durrington PN; Faergeman O; Frohlich J; Furberg CD; Gagne C; Haffner SM; Humphries SE; Jungner I; Krauss RM; Kwiterovich P; Marcovina S; Packard CJ; Pearson TA; Reddy KS; Rosenson R; Sarrafzadegan N; Sniderman AD; Stalenhoef AF; Stein E; Talmud PJ; Tonkin AM; Walldius G; Williams KM
    J Intern Med; 2006 Mar; 259(3):247-58. PubMed ID: 16476102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoproteins as markers and managers of coronary risk.
    Chan DC; Watts GF
    QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
    Jungner I; Sniderman AD; Furberg C; Aastveit AH; Holme I; Walldius G
    Am J Cardiol; 2006 Apr; 97(7):943-6. PubMed ID: 16563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis.
    Drexel H; Aczel S; Marte T; Vonbank A; Saely CH
    Atherosclerosis; 2010 Feb; 208(2):484-9. PubMed ID: 19748621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease.
    Zambon A; Brown BG; Deeb SS; Brunzell JD
    J Intern Med; 2006 May; 259(5):473-80. PubMed ID: 16629853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].
    Onat A; Ozhan H; Can G; Hergenç G; Karabulut A; Albayrak S
    Anadolu Kardiyol Derg; 2007 Jun; 7(2):128-33. PubMed ID: 17513206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the detection and treatment of atherogenic low-density lipoproteins.
    Sniderman A; Kwiterovich PO
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.
    Marcovina S; Packard CJ
    J Intern Med; 2006 May; 259(5):437-46. PubMed ID: 16629849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein measurements: is more widespread use clinically indicated?
    Davidson MH
    Clin Cardiol; 2009 Sep; 32(9):482-6. PubMed ID: 19743499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of serum lipid profile and serum apolipoproteins A1 and B in Indian male violent criminal offenders.
    Chakrabarti N; Sinha VK
    Crim Behav Ment Health; 2006; 16(3):177-82. PubMed ID: 16838385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.
    Juonala M; Viikari JS; Kähönen M; Solakivi T; Helenius H; Jula A; Marniemi J; Taittonen L; Laitinen T; Nikkari T; Raitakari OT
    J Am Coll Cardiol; 2008 Jul; 52(4):293-9. PubMed ID: 18634985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
    Davidson MH
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
    [No Abstract]   [Full Text] [Related]  

  • 18. Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus.
    Matsumoto K; Fujita N; Nakamura K; Senoo T; Tominaga T; Ueki Y
    Diabetes Res Clin Pract; 2008 Oct; 82(1):93-7. PubMed ID: 18684539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of apolipoprotein B and non-high-density lipoprotein cholesterol for identifying coronary artery disease risk based on receiver operating curve analysis.
    Levinson SS
    Am J Clin Pathol; 2007 Mar; 127(3):449-55. PubMed ID: 17276939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.